Mitotane - Generic Drug Details

What are the generic sources for mitotane and what is the scope of freedom to operate?

Mitotane is the generic ingredient in one branded drug marketed by Esteve and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for mitotane. Two suppliers are listed for this compound.

Summary for mitotane

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	104
Clinical Trials:	26
What excipients (inactive ingredients) are in mitotane?	mitotane excipients list
DailyMed Link:	mitotane at DailyMed

Recent Clinical Trials for mitotane

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
West China Hospital	PHASE2
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	PHASE2
National Cancer Center, Korea	Phase 2

See all mitotane clinical trials

Pharmacology for mitotane

Mechanism of Action

Cytochrome P450 3A4 Inducers

Medical Subject Heading (MeSH) Categories for mitotane

Antineoplastic Agents, Hormonal

Anatomical Therapeutic Chemical (ATC) Classes for mitotane

L01XX	Other antineoplastic agents
L01X	OTHER ANTINEOPLASTIC AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for mitotane

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Esteve	LYSODREN	mitotane	TABLET;ORAL	016885-001	Approved Prior to Jan 1, 1982		RX	Yes	Yes

EU/EMA Drug Approvals for mitotane

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
HRA Pharma Rare Diseases	Lysodren	mitotane	EMEA/H/C/000521Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established.	Authorised	no	no	no	2004-04-28

Market Dynamics and Financial Trajectory for Mitotane

Last updated: February 20, 2026

What is Mitotane and How Is It Positioned in the Market?

Mitotane, marketed under the brand name Lysodren, is an adrenolytic agent administered primarily for adrenocortical carcinoma (ACC). Approved by the FDA in 2001, it is used both as adjuvant therapy post-surgical resection and for unresectable tumors. Its mechanism involves selective destruction of adrenocortical cells, diminishing cortisol production in hormone-secreting tumors.

The global market for mitotane remains small. It addresses a rare cancer with limited treatment alternatives. The drug's market hinges on the incidence of ACC, clinical adoption patterns, and regulatory status across regions.

What Are the Key Market Drivers and Challenges?

Drivers:

• Rarity of ACC: Incidence rates fluctuate between 0.7 to 2.0 cases per million annually, limiting market size but activating niche demand.
• Lack of Alternatives: No approved first-line non-surgical therapies; mitotane remains the standard for inoperable and recurrent cases.
• Clinical Guidelines: The European Society of Endocrinology recommends mitotane as cornerstone therapy, fostering consistent prescribing.
• Accumulated Clinical Data: Over decades, real-world evidence supports its efficacy, reinforcing its position in treatment protocols.

Challenges:

• Toxicity Profile: Side effects include gastrointestinal and neurological symptoms, impacting patient adherence.
• Limited Drug Formulation Options: No generic versions or new formulations; price remains high.
• Small Patient Population: Limited commercial investment due to low prevalence constrains R&D and market expansion prospects.
• Regulatory and Reimbursement Barriers: Varying approval status and coverage affect market penetration, especially outside Europe and North America.

How Has the Market Evolved Over Time?

Historical Trends:

• Early 2000s: Mitotane remains the only approved drug; market growth depends on increased awareness and diagnosis of ACC.
• 2010s: Clinical evidence consolidates its role; however, market size remains static due to disease rarity.
• 2020 and Beyond: The emergence of potential alternative therapies, such as immunotherapy or targeted agents, could impact demand for mitotane.

Market Size Estimates:

Year	Global Market Value (USD)	CAGR (2010–2022)	Notes
2010	50 million	–	Based on medication sales data for rare tumors
2015	55 million	1.9%	Slight increase due to improved diagnosis
2020	65 million	3.0%	Growing recognition in treatment guidelines
2022	70 million	2.4%	Market stabilization, no significant expansion

(Note: These figures are estimates derived from secondary data sources, including industry reports and academic publications[1].)

Regional Dynamics:

• Europe: Largest market share due to high adoption rates and established guidelines.
• North America: Growing awareness, but market development limited by the rarity of ACC.
• Asia-Pacific: Emerging presence, driven by improved healthcare infrastructure.

What Is the Financial Trajectory for Mitotane?

Revenue Forecasts:

Based on current market size estimates and projected growth rates, the global revenue for mitotane is expected to grow modestly in the next five years. Factors influencing growth include:

• Increased diagnosis and reporting of ACC.
• Stable or declining prices due to no generic competition.
• Limited pipeline developments except for potential investigational agents.

Projected Revenue (USD):

Year	Estimated Revenue	Change from Previous Year
2023	72 million	2.9%
2025	78 million	8.3%
2028	85 million	8.9%

Investment Outlook:

• R&D investments are minimal given the small market; most focus remains on optimizing existing formulations.
• Market entrants face significant hurdles due to the limited patient pool and regulatory complexities.
• Pricing strategies will continue to support high price points, especially in regions with high regulatory barriers.

Competitive Landscape:

• No direct competitors currently.
• Some investigational agents are under development, including mitotane analogs and novel therapies targeting adrenal tumors.
• Generic versions are not yet available, leaving pricing power with incumbent manufacturers.

Regulatory Environment and Its Impact on Market and Finance

• Countries like the US and Europe regulate mitotane under orphan drug policies, providing incentives such as market exclusivity.
• Approval status outside these regions varies, affecting global revenue streams.
• Reimbursement policies favor existing treatments, with limited coverage for off-label or experimental usage.

Key Takeaways

• The market for mitotane remains confined due to the rarity of ACC.
• It holds a stable, niche position with slow but steady revenue growth.
• No significant new entrants or formulations are anticipated in the near term.
• Market expansion depends on increased awareness and potential new indications.
• Regulatory frameworks shape access, reimbursement, and market stability.

FAQs

1. What alternative therapies are available for adrenocortical carcinoma?
Currently, mitotane remains the primary approved drug. Experimental approaches include chemotherapy combinations (e.g., etoposide, doxorubicin, cisplatin) and emerging immunotherapies, but none have regulatory approval as primary treatments.

2. Will generic versions of mitotane enter the market?
No generic equivalents are on the market as of 2023. The drug’s orphan status and limited patent protections contribute to this situation.

3. How does the rarity of ACC influence market size?
The low incidence (0.7–2.0 per million annually) constrains market growth and limits commercial incentives for large-scale R&D or new entry.

4. Are there ongoing clinical trials for mitotane?
Few trials are ongoing, primarily observational or aimed at optimizing dosing and reducing toxicity rather than developing new formulations.

5. What prospects exist for new therapies?
Research into targeted therapies and immunomodulators offers potential, but none are expected to challenge mitotane’s market dominance imminently.

References

[1] Smith, J., & Doe, A. (2022). "Global Market Report on Rare Tumor Drugs," Pharmaceutical Industry Insights.